Escitalopram vs Sitagliptin: side-by-side comparison
Escitalopram (Selective serotonin reuptake inhibitor (SSRI)) and Sitagliptin (DPP-4 inhibitor) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Escitalopram | Sitagliptin |
|---|---|---|
| Therapeutic class | Selective serotonin reuptake inhibitor (SSRI) | DPP-4 inhibitor |
| CAS | 128196-01-0 | 486460-32-6 |
| ATC | N06AB10 | A10BH01 |
| Molecular weight | 324.39 g/mol | 407.31 g/mol |
| Brands with this active ingredient | 1 | 1 |
What they share
Escitalopram and Sitagliptin share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Escitalopram acts by a different mechanism than Sitagliptin, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Escitalopram: L'escitalopram inhibe sélectivement le transporteur de recapture de la sérotonine (SERT) au niveau de la fente synaptique, augmentant la disponibilité de la sérotonine pour les récepteurs postsynaptiques. Sitagliptin: La sitagliptine inhibe de façon réversible la DPP-4, sérine protéase responsable de la dégradation rapide du glucagon-like peptide 1 (GLP-1) et du polypeptide insulinotrope glucose-dépendant (GIP).
Indications compared
Escitalopram: L'escitalopram est autorisé dans la dépression caractérisée, le trouble anxieux généralisé, l'anxiété sociale, le trouble panique et le trouble obsessionnel compulsif, avec des variations d'autorisation selon les pays. Sitagliptin: La sitagliptine est autorisée chez l'adulte atteint de diabète de type 2, seule ou en association à d'autres antidiabétiques, pour améliorer le contrôle glycémique.
Safety profile
Escitalopram: Les effets indésirables fréquents comprennent nausées, céphalées, troubles de la fonction sexuelle, fatigue, troubles du sommeil et augmentation de la sudation, plus marqués durant les 2 à 4 premières semaines. Sitagliptin: La sitagliptine est généralement bien tolérée.
Questions fréquentes
Is Escitalopram better than Sitagliptin? ▾
Escitalopram and Sitagliptin are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Escitalopram and Sitagliptin be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Escitalopram
Products with Sitagliptin
Les informations publiées sur ce site sont fournies à titre documentaire et pédagogique. Elles ne remplacent pas l'avis d'un professionnel de santé qualifié.